Free Case Evaluation
|
Trasylol Studies
Two recent studies show that the drug Trasylol, which is commonly given to reduce bleeding during heart surgery, can double the risk of renal failure, heart attack, stroke and death.
Rresearchers stated that pre-marketing studies were not adequate to detect the risk of serious complications. This Trasylol heart surgery study found that Trasylol use doubled patients’ risk of renal failure, heart attack, heart failure, stroke, brain disease and overall risk of death. [Trasylol statistics]
The NEJM study
The first study in the New England Journal of Medicine in January 2006, indicates that patients given Trasylol during heart surgery were twice as likely to suffer these serious adverse reactions.
Some subjects in the study were given alternative medications (aminocaproic acid and tranexamic acid) to reduce bleeding. Neither of these generic medications was associated with an increased risk of serious adverse reactions.
The study’s authors concluded that “Our findings indicate that reconsideration of the safety of aprotinin [Trasylol] among patients undergoing cardiac surgery is warranted and indicate replacement of aprotinin with either aminocaproic acid or tranexamic acid.”
The Transfusion study
A second study, entitled “A Propensity Score Case-Control Comparison of Aprotinin and Tranexamic Acid in High-Transfusion-Risk Cardiac Surgery” by Dr. Keyvan Karkouti et al. was published in the January 20, 2006 online medical journal Transfusion.
The Transfusion study suggested that Trasylol administration increased the risk for renal dysfunction or failure. Renal dysfunction and renal failure have previously been reported in patients receiving Trasylol.
Rresearchers stated that pre-marketing studies were not adequate to detect the risk of serious complications. This Trasylol heart surgery study found that Trasylol use doubled patients’ risk of renal failure, heart attack, heart failure, stroke, brain disease and overall risk of death. [Trasylol statistics]
Trasylol can double the risk of renal failure, heart attack, stroke and death.
The first study in the New England Journal of Medicine in January 2006, indicates that patients given Trasylol during heart surgery were twice as likely to suffer these serious adverse reactions.
Some subjects in the study were given alternative medications (aminocaproic acid and tranexamic acid) to reduce bleeding. Neither of these generic medications was associated with an increased risk of serious adverse reactions.
The study’s authors concluded that “Our findings indicate that reconsideration of the safety of aprotinin [Trasylol] among patients undergoing cardiac surgery is warranted and indicate replacement of aprotinin with either aminocaproic acid or tranexamic acid.”
The Transfusion study
A second study, entitled “A Propensity Score Case-Control Comparison of Aprotinin and Tranexamic Acid in High-Transfusion-Risk Cardiac Surgery” by Dr. Keyvan Karkouti et al. was published in the January 20, 2006 online medical journal Transfusion.
The Transfusion study suggested that Trasylol administration increased the risk for renal dysfunction or failure. Renal dysfunction and renal failure have previously been reported in patients receiving Trasylol.
The Hissey Kientz Law Firm attorneys can handle lawsuits, claims and settlements in Alabama, Alaska, Arizona,
Arkansas, California, Colorado, Connecticut, D.C., Delaware, Florida, Georgia, Hawaii, Idaho, Illinois,
Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi,
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota,
Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont,
Virginia, Washington, West Virginia,
Wisconsin and Wyoming. Our experienced lawyers can help.